Running Interference: RNAi with Silence Therapeutics' Craig Tooman

We love to hear from our listeners. Send us a message. Fresh on the heels of his appointment as President & CEO at Silence Therapeutics, Craig Tooman joins the Business of Biotech to share how he applies his finance-minded leadership to steward the advance of the company's deepening pipeline of gene silencing candidates. Tooman also shares insight into the IP and the people responsible for managing that deep pipeline, which spans indications from hematology to cardiovascular disease...